StockCall Review on Dynavax and GlaxoSmithKline: Pharma Stocks Bet on Drug Approvals

Tue Feb 12, 2013 8:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130212:nPn2123895


LONDON,  February 12, 2013  /PRNewswire/ --

Any drug company's stock price hinges on the performance of its drugs. One of
the very first steps involved in marketing a drug is getting the approval of
FDA. Dynavax Technologies Corporation (NASDAQ: DVAX) is one such company that
pointed out that the point recently. The stock plummeted when its drug candidate
received poor reviews. However, the same Hepatitis B drug is now waiting for the
final approval and the FDA's decision will have a major impact on the future
direction taken by Dynavax Technologies stock. Similarly, GlaxoSmithKline Plc
(NYSE: GSK) is also awaiting FDA's decision for its major drug candidates. The
drug industry is also dealing with problems like patent expiries and falling
revenues as GlaxoSmithKline posted weak results. The drug industry is expected
to see consolidation this year as major companies may acquire smaller biotech
firms to plug the losses caused by expired patents. StockCall analysts initiated
preliminary technical research on Dynavax and GlaxoSmithKline. These free
reports are accessible by signing today at  http://www.stockcall.com/register

GlaxoSmithKline Posts Q4 Results

GlaxoSmithKline Plc reported lower income for its fourth quarter of the year.
The company earned  57 cents  per share, down from  90 cents  per share it had
earned a year earlier. Its revenue for the quarter stood at  $11 billion.
Overall, the results were lower-than-expected. However, all is not bad when it
comes to GlaxoSmithKline. The company sports healthy margins. It is also doing
well on the growth front as it finalized the acquisition of Human Genome
Sciences. With this acquisition, the company also gained the access to Benlysta,
which is used to treat Lupus. Register now to download the free research on
GlaxoSmithKline at  http://www.StockCall.com/GSK021213.pdf   

GlaxoSmithKline stock increased 1.72 percent in the past 12 months and the
company is taking steps to improve its stock price performance. It is looking to
expand its footprints in emerging markets. The company recently inked a new
joint venture in  India  for developing a multi-use vaccine for ailments such as
Hepatitis B. GlaxoSmithKline also has strong pipeline as it expects to get
reviews for six of its drugs in 2013. These drugs may prove to be a major
catalyst for GlaxoSmithKline stock, as and when they receive approval.
Improvement in global and European economy is also likely to have positive
impact on the stock. Apart from growth prospects, the stock also offers
mouthwatering dividend yield of 5.10 percent.

Dynavax Technologies Waits for FDA Decision

Dynavax Technologies Corporation is waiting for FDA's decision for its Hepatitis
B drug Heplisav. The decision is due out on  February 24th. If approved, the
drug may open up a lucrative market for Dynavax Technologies. However, there are
certain apprehensions about the drug receiving unconditional approval. The free
technical analysis on Dynavax Technologies is available by signing up at 
http://www.StockCall.com/DVAX021213.pdf   

Dynavax Technologies was thoroughly beaten down late last year, after getting
negative safety vote for Heplisav. However, since then the stock has recovered
nicely. It is currently trading slightly above its 20-day moving average price
of  $3.26, showing neutral trend. However, it is expected to breakout, if its
Hepatitis B drug receives the approval. There are quite high chances of the drug
receiving approval and the stock looks attractive at the moment.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up
today to talk to our financial analyst at  http://www.stockcall.com   

SOURCE  StockCall.com


William T. Knight, Email: info@stockcall.com, Contact Number: +1-646-396-9857
(9:00 am EST - 01:30 pm EST)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.